{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:35:59Z","timestamp":1794072959419,"version":"4.8.0"},"reference-count":122,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Coagulation factor VIII (FVIII) is essential for hemostasis. After activation, it combines with activated FIX (FIXa) on anionic membranes to form the intrinsic Xase enzyme complex, responsible for activating FX in the rate-limiting step of sustained coagulation. Hemophilia A (HA) and hemophilia B are due to inherited deficiencies in the activity of FVIII and FIX, respectively. Treatment of HA over the last decade has benefited from an improved understanding of FVIII biology, including its secretion pathway, its interaction with von Willebrand factor in circulation, the biochemical nature of its FIXa cofactor activity, the regulation of activated FVIII by inactivation pathways, and its surprising immunogenicity. This has facilitated biotechnology innovations with first-in-class examples of several new therapeutic modalities recently receiving regulatory approval for HA, including FVIII-mimetic bispecific antibodies and recombinant adeno-associated viral (rAAV) vector\u2013based gene therapy. Biological insights into FVIII also guide the development and use of gain-of-function FVIII variants aimed at addressing the limitations of first-generation rAAV vectors for HA. Several gain-of-function FVIII variants designed to have improved secretion are currently incorporated in second-generation rAAV vectors and have recently entered clinical trials. Continued mutually reinforcing advancements in the understanding of FVIII biology and treatments for HA are necessary to achieve the ultimate goal of hemophilia therapy: normalizing hemostasis and optimizing well-being with minimal treatment burden for all patients worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023023275","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T15:53:42Z","timestamp":1722527622000},"page":"2185-2197","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Coagulation factor VIII: biological basis of emerging hemophilia A therapies"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6772-4140","authenticated-orcid":false,"given":"Benjamin J.","family":"Samelson-Jones","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA"},{"name":"2Division of Hematology, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children\u2019s Hospital of Philadelphia, Philadelphia PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-4231","authenticated-orcid":false,"given":"Bhavya S.","family":"Doshi","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA"},{"name":"2Division of Hematology, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children\u2019s Hospital of Philadelphia, Philadelphia PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-1559","authenticated-orcid":false,"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA"},{"name":"2Division of Hematology, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children\u2019s Hospital of Philadelphia, Philadelphia PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2024112116204770400_bib1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2024112116204770400_bib2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","article-title":"Novel approaches to hemophilia therapy: successes and challenges","volume":"130","author":"Arruda","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2024112116204770400_bib3","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of AAV liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"2024112116204770400_bib4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74(1)","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"2024112116204770400_bib5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"21","key":"2024112116204770400_bib6","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.2023023276","article-title":"Blood coagulation factor IX: structural insights impacting hemophilia B therapy","volume":"144","author":"Bos","year":"2024","journal-title":"Blood"},{"issue":"24","key":"2024112116204770400_bib7","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A\u00a0conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2024112116204770400_bib8","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"issue":"14","key":"2024112116204770400_bib9","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1074\/jbc.273.14.8537","article-title":"Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin","volume":"273","author":"Pipe","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"2024112116204770400_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri.2016.62","article-title":"The unfolded protein response in immunity and inflammation","volume":"16","author":"Grootjans","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"47","key":"2024112116204770400_bib11","doi-asserted-by":"crossref","first-page":"18525","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024112116204770400_bib12","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2024112116204770400_bib13","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"2024112116204770400_bib14","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1111\/jth.12749","article-title":"Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy","volume":"12","author":"Greene","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024112116204770400_bib15","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1038\/s41467-024-51296-8","article-title":"Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice","volume":"15","author":"Sternberg","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"2024112116204770400_bib16","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood.V84.12.4214.bloodjournal84124214","article-title":"Role of the B domain for factor VIII and factor V expression and function","volume":"84","author":"Pittman","year":"1994","journal-title":"Blood"},{"issue":"21","key":"2024112116204770400_bib17","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2024112116204770400_bib18","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1074\/jbc.270.17.10297","article-title":"A\u00a0110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells","volume":"270","author":"Marquette","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"2024112116204770400_bib19","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol Ther"},{"issue":"2","key":"2024112116204770400_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ng1153","article-title":"Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex","volume":"34","author":"Zhang","year":"2003","journal-title":"Nat Genet"},{"issue":"1","key":"2024112116204770400_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1432-1033.1995.tb20776.x","article-title":"Novel forms of B-domain deleted recombinant factor VIII molecules. Construction and biochemical characterization","volume":"232","author":"Lind","year":"1995","journal-title":"Eur J Biochem"},{"issue":"11","key":"2024112116204770400_bib22","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in\u00a0vivo functional characterization of B-domain-deleted FVIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"issue":"9","key":"2024112116204770400_bib23","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.83.9.2979","article-title":"Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate and plasma","volume":"83","author":"Andersson","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2024112116204770400_bib24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2516.2009.02026.x","article-title":"Functional roles of the factor VIII B domain","volume":"15","author":"Pipe","year":"2009","journal-title":"Haemophilia"},{"issue":"5","key":"2024112116204770400_bib25","doi-asserted-by":"crossref","first-page":"e0233576","DOI":"10.1371\/journal.pone.0233576","article-title":"Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII","volume":"15","author":"Qu","year":"2020","journal-title":"PLoS One"},{"issue":"8","key":"2024112116204770400_bib26","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jth.14204","article-title":"In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications","volume":"16","author":"Canis","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"46","key":"2024112116204770400_bib27","doi-asserted-by":"crossref","first-page":"32539","DOI":"10.1074\/jbc.274.46.32539","article-title":"Mannose-dependent endoplasmic reticulum (ER)-Golgi intermediate compartment-53-mediated ER to Golgi trafficking of coagulation factors V and VIII","volume":"274","author":"Moussalli","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2024112116204770400_bib28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1182\/bloodadvances.2022008788","article-title":"Separate roles of LMAN1 and MCFD2 in ER-to-Golgi trafficking of FV and FVIII","volume":"7","author":"Zhang","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024112116204770400_bib29","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2024112116204770400_bib30","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/sj.mt.6300308","article-title":"Correction of murine hemophilia A and immunological differences of factor VIII variants delivered by helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Mol Ther"},{"issue":"17","key":"2024112116204770400_bib31","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024112116204770400_bib32","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/s41467-020-15192-1","article-title":"Improved secretion of glycoproteins using an N-glycan-restricted passport sequence tag recognized by cargo receptor","volume":"11","author":"Yagi","year":"2020","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2024112116204770400_bib33","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2023-180803","article-title":"GO-8: stable expression of factor VIII over 5 years following adeno-associated gene transfer in subjects with hemophilia A using a novel human factor VIII variant [abstract]","volume":"142","author":"Chowdary","year":"2023","journal-title":"Blood"},{"issue":"16","key":"2024112116204770400_bib34","doi-asserted-by":"crossref","first-page":"e89371","DOI":"10.1172\/jci.insight.89371","article-title":"Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models","volume":"1","author":"Siner","year":"2016","journal-title":"JCI Insight"},{"issue":"8","key":"2024112116204770400_bib35","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jtha.2023.04.012","article-title":"Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice","volume":"21","author":"Nguyen","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"39","key":"2024112116204770400_bib36","doi-asserted-by":"crossref","first-page":"24121","DOI":"10.1074\/jbc.272.39.24121","article-title":"Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII","volume":"272","author":"Swaroop","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"41","key":"2024112116204770400_bib37","doi-asserted-by":"crossref","first-page":"38345","DOI":"10.1074\/jbc.M206959200","article-title":"High level expression of recombinant porcine coagulation factor VIII","volume":"277","author":"Doering","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"2024112116204770400_bib38","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"2024112116204770400_bib39","doi-asserted-by":"crossref","first-page":"14036","DOI":"10.1038\/mtm.2014.36","article-title":"Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery","volume":"1","author":"Brown","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"2024112116204770400_bib40","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"key":"2024112116204770400_bib41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","article-title":"Minimal essential human factor VIII alterations enhance secretion and gene therapy efficiency","volume":"19","author":"Cao","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2024112116204770400_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"Zakas","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2024112116204770400_bib43","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V92.11.3983","article-title":"The life cycle of coagulation factor VIII in view of its structure and function","volume":"92","author":"Lenting","year":"1998","journal-title":"Blood"},{"issue":"16","key":"2024112116204770400_bib44","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2024112116204770400_bib45","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1182\/blood.2023023277","article-title":"How unique structural adaptations support and coordinate the complex function of von Willebrand factor","volume":"144","author":"Lenting","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2024112116204770400_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024112116204770400_bib47","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V87.6.2292.bloodjournal8762292","article-title":"Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C","volume":"87","author":"Koppelman","year":"1996","journal-title":"Blood"},{"issue":"17","key":"2024112116204770400_bib48","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1073\/pnas.86.17.6508","article-title":"Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin","volume":"86","author":"Hill-Eubanks","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2024112116204770400_bib49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1182\/blood.V63.6.1303.1303","article-title":"Stabilisation of thrombin activated porcine factor VIII:C by factor IXa and phospholipid","volume":"63","author":"Lollar","year":"1984","journal-title":"Blood"},{"issue":"2","key":"2024112116204770400_bib50","first-page":"193","article-title":"Regulation of factor VIIIa in the intrinsic factor Xase","volume":"82","author":"Fay","year":"1999","journal-title":"Thromb Haemost"},{"issue":"11","key":"2024112116204770400_bib51","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1182\/bloodadvances.2021005874","article-title":"SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa\/IXa","volume":"6","author":"Childers","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2024112116204770400_bib52","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood.2020005593","article-title":"Factor VIII-driven changes in activated factor IX explored by hydrogen-deuterium exchange mass spectrometry","volume":"136","author":"Freato","year":"2020","journal-title":"Blood"},{"key":"2024112116204770400_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0268-960X(03)00025-0","article-title":"Activation of factor VIII and mechanisms of cofactor action","volume":"18(1)","author":"Fay","year":"2004","journal-title":"Blood Rev"},{"issue":"30","key":"2024112116204770400_bib54","doi-asserted-by":"crossref","first-page":"19049","DOI":"10.1074\/jbc.273.30.19049","article-title":"The A2 subunit of factor VIIIa modulates the active site of factor IXa","volume":"273","author":"Fay","year":"1998","journal-title":"J\u00a0Biol Chem"},{"issue":"41","key":"2024112116204770400_bib55","doi-asserted-by":"crossref","first-page":"25332","DOI":"10.1074\/jbc.271.41.25332","article-title":"Calcium binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding","volume":"271","author":"Lenting","year":"1996","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"2024112116204770400_bib56","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"2024112116204770400_bib57","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"issue":"15","key":"2024112116204770400_bib58","doi-asserted-by":"crossref","first-page":"12434","DOI":"10.1074\/jbc.M009539200","article-title":"Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXa","volume":"276","author":"Fay","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"16","key":"2024112116204770400_bib59","doi-asserted-by":"crossref","first-page":"15763","DOI":"10.1074\/jbc.M400568200","article-title":"Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain","volume":"279","author":"Nogami","year":"2004","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"2024112116204770400_bib60","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/s-0038-1637745","article-title":"Contribution of factor VIII A2 domain residues 400-409 to a factor X-interactive site in the factor Xase complex","volume":"118","author":"Takeyama","year":"2018","journal-title":"Thromb Haemost"},{"issue":"3","key":"2024112116204770400_bib61","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/bi201731p","article-title":"Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase","volume":"51","author":"Takeyama","year":"2012","journal-title":"Biochemistry"},{"issue":"43","key":"2024112116204770400_bib62","doi-asserted-by":"crossref","first-page":"31000","DOI":"10.1074\/jbc.274.43.31000","article-title":"Role of factor VIII C2 domain in factor VIII binding to factor Xa","volume":"274","author":"Nogami","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2024112116204770400_bib63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0304-4157(98)00018-5","article-title":"Lipid-protein interactions in blood coagulation","volume":"1376","author":"Zwaal","year":"1998","journal-title":"Biochim Biophys Acta"},{"issue":"14","key":"2024112116204770400_bib64","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A\u00a0factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2024112116204770400_bib122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1538-7836.2011.04545.x","article-title":"Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop","volume":"10","author":"Selvaraj","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024112116204770400_bib74","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbrc.2022.02.066","article-title":"A\u00a0high efficient FVIII variant corrects bleeding in hemophilia A mouse model","volume":"637","author":"Mashausi","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2024112116204770400_bib72","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/bloodadvances.2022008187","article-title":"Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential","volume":"7","author":"Nakajima","year":"2023","journal-title":"Blood Adv"},{"key":"2024112116204770400_bib73","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.omtm.2019.12.019","article-title":"Identification of key coagulation activity determining elements in canine factor VIII","volume":"17","author":"Firrman","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"22","key":"2024112116204770400_bib86","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","article-title":"Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa","volume":"94","author":"Pipe","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2024112116204770400_bib84","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1046\/j.1538-7836.2003.00348.x","article-title":"An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa","volume":"1","author":"Gale","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024112116204770400_bib76","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2014-02-555656","article-title":"Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models","volume":"125","author":"Leong","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2024112116204770400_bib75","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2024112116204770400_bib65","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1042\/BCJ20160336","article-title":"Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site","volume":"473","author":"Kristensen","year":"2016","journal-title":"Biochem J"},{"issue":"29","key":"2024112116204770400_bib66","doi-asserted-by":"crossref","first-page":"e2401136121","DOI":"10.1073\/pnas.2401136121","article-title":"An RNA aptamer exploits exosite-dependent allostery to achieve specific inhibition of coagulation factor IXa","volume":"121","author":"Kolyadko","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024112116204770400_bib67","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2018.04.016","article-title":"The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity","volume":"166","author":"Minami","year":"2018","journal-title":"Thromb Res"},{"issue":"45","key":"2024112116204770400_bib68","doi-asserted-by":"crossref","first-page":"15198","DOI":"10.1074\/jbc.RA120.015325","article-title":"Exosite binding drives substrate affinity for the activation of coagulation factor X by the intrinsic Xase complex","volume":"295","author":"Basavaraj","year":"2020","journal-title":"J\u00a0Biol Chem"},{"issue":"Pt 2","key":"2024112116204770400_bib69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj3100539","article-title":"Binding of blood coagulation factor VIII and its light chain to phosphatidylserine\/phosphatidylcholine bilayers as measured by ellipsometry","volume":"310","author":"Spaargaren","year":"1995","journal-title":"Biochem J"},{"issue":"3","key":"2024112116204770400_bib70","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj2230599","article-title":"Binding of human blood-coagulation factors IXa and X to phospholipid membranes","volume":"223","author":"Mertens","year":"1984","journal-title":"Biochem J"},{"issue":"19","key":"2024112116204770400_bib71","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1074\/jbc.271.19.11120","article-title":"Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine","volume":"271","author":"Gilbert","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"2024112116204770400_bib77","first-page":"100338","article-title":"OC 73.5 Delineating the role of physiologic ligands on FVIIIa inactivation","volume":"7(suppl 2)","author":"Morris","year":"2023","journal-title":"RPTH"},{"issue":"19","key":"2024112116204770400_bib78","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1016\/S0021-9258(18)98924-6","article-title":"Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog","volume":"266","author":"Lollar","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2024112116204770400_bib79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V97.3.685","article-title":"Hemophilia A mutations associated with 1-stage\/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa","volume":"97","author":"Pipe","year":"2001","journal-title":"Blood"},{"issue":"30","key":"2024112116204770400_bib80","doi-asserted-by":"crossref","first-page":"20139","DOI":"10.1016\/S0021-9258(18)54901-2","article-title":"Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity","volume":"266","author":"Fay","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"24","key":"2024112116204770400_bib81","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1074\/jbc.M708985200","article-title":"Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V","volume":"283","author":"Gale","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2024112116204770400_bib82","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2008-02-142158","article-title":"Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface","volume":"112","author":"Wakabayashi","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2024112116204770400_bib83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1538-7836.2008.03256.x","article-title":"Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations","volume":"7","author":"Wakabayashi","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"15","key":"2024112116204770400_bib85","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/bloodadvances.2023012391","article-title":"The combination of Asp519Val\/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential","volume":"8","author":"Nakajima","year":"2024","journal-title":"Blood Adv"},{"issue":"26","key":"2024112116204770400_bib87","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2010-06-293308","article-title":"In\u00a0vivo efficacy of platelet-delivered, high specific activity factor VIII variants","volume":"116","author":"Greene","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2024112116204770400_bib88","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"2024112116204770400_bib89","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/bloodadvances.2021004742","article-title":"Identification of coagulation factor IX variants with enhanced activity through ancestral sequence reconstruction","volume":"5","author":"Knight","year":"2021","journal-title":"Blood Adv"},{"key":"2024112116204770400_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-marine-022521-102228","article-title":"The Goldilocks principle: a unifying perspective on biochemical adaptation to abiotic stressors in the sea","volume":"14(1)","author":"Somero","year":"2022","journal-title":"Ann Rev Mar Sci"},{"issue":"8943","key":"2024112116204770400_bib91","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"2024112116204770400_bib92","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/bloodadvances.2020003755","article-title":"Significant differences in single-platelet biophysics exist across species but attenuate during clot formation","volume":"5","author":"Oshinowo","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2024112116204770400_bib93","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2024112116204770400_bib94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-0037-1614081","article-title":"Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects","volume":"84","author":"Reding","year":"2000","journal-title":"Thromb Haemost"},{"issue":"23","key":"2024112116204770400_bib95","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A","volume":"130","author":"Zerra","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2024112116204770400_bib96","first-page":"290","article-title":"Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells","volume":"142","author":"Kaczmarek","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024112116204770400_bib97","doi-asserted-by":"crossref","first-page":"e142906","DOI":"10.1172\/JCI142906","article-title":"B\u00a0cell-activating factor modulates the factor VIII immune response in hemophilia A","volume":"131","author":"Doshi","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"22","key":"2024112116204770400_bib98","doi-asserted-by":"crossref","first-page":"e159925","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J\u00a0Clin Invest"},{"issue":"24","key":"2024112116204770400_bib102","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1074\/jbc.270.24.14505","article-title":"Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII","volume":"270","author":"Healey","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"2024112116204770400_bib103","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood.V97.4.966","article-title":"Multiple VH genes are\u00a0used to assemble human antibodies directed toward the A3-C1 domains of\u00a0factor VIII","volume":"97","author":"van den Brink","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2024112116204770400_bib104","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V82.8.2452.2452","article-title":"Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction","volume":"82","author":"Gilles","year":"1993","journal-title":"Blood"},{"issue":"10","key":"2024112116204770400_bib105","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","article-title":"The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups","volume":"89","author":"Prescott","year":"1997","journal-title":"Blood"},{"issue":"13","key":"2024112116204770400_bib99","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","article-title":"Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation","volume":"110","author":"Meeks","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2024112116204770400_bib100","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2012-09-456582","article-title":"The diversity of the immune response to the A2 domain of human factor VIII","volume":"121","author":"Markovitz","year":"2013","journal-title":"Blood"},{"issue":"16","key":"2024112116204770400_bib101","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","article-title":"High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors","volume":"128","author":"Batsuli","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2024112116204770400_bib106","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"issue":"26","key":"2024112116204770400_bib107","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2013-08-519124","article-title":"Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024112116204770400_bib108","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V98.1.13","article-title":"Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII","volume":"98","author":"Spiegel","year":"2001","journal-title":"Blood"},{"issue":"11","key":"2024112116204770400_bib109","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2004.00918.x","article-title":"T\u00a0cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects","volume":"2","author":"Hu","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024112116204770400_bib110","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/bjh.17227","article-title":"Characterisation and application of recombinant FVIII-neutralising antibodies from haemophilia A inhibitor patients","volume":"193","author":"Coxon","year":"2021","journal-title":"Br J Haematol"},{"issue":"8","key":"2024112116204770400_bib111","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024112116204770400_bib112","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024112116204770400_bib113","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/bloodadvances.2017013482","article-title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity","volume":"2","author":"Ettinger","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"2024112116204770400_bib114","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clim.2011.11.010","article-title":"Effect of HLA DR epitope de-immunization of factor VIII in\u00a0vitro and in\u00a0vivo","volume":"142","author":"Moise","year":"2012","journal-title":"Clin Immunol"},{"issue":"14","key":"2024112116204770400_bib115","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/bloodadvances.2021005758","article-title":"Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII","volume":"6","author":"Vander Kooi","year":"2022","journal-title":"Blood Adv"},{"key":"2024112116204770400_bib116","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy for hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"2024112116204770400_bib117","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2023.05.011","article-title":"A\u00a0review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?","volume":"21","author":"Valentino","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"2024112116204770400_bib118","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1182\/bloodadvances.2021006359","article-title":"Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice","volume":"6","author":"Lundgren","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2024112116204770400_bib119","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol Ther"},{"issue":"4","key":"2024112116204770400_bib120","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","article-title":"Immune tolerance induction by hepatic gene transfer: first-in-human evidence","volume":"32","author":"Kaczmarek","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"2024112116204770400_bib121","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.13862","article-title":"Achieving the unimaginable: health equity in haemophilia","volume":"26","author":"Skinner","year":"2020","journal-title":"Haemophilia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/21\/2185\/2314043\/blood_bld-2023-023275-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/21\/2185\/2314043\/blood_bld-2023-023275-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T11:18:45Z","timestamp":1732533525000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/21\/2185\/517262\/Coagulation-factor-VIII-biological-basis-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":122,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023275","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}